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Abstract—Intensive care unit patients may have a better 
glycaemic management with the right control protocol.   Results 
of virtual trial performance on Malaysian critically-ill patients 
adopting a model-derived and model-based control protocol 
known as SPRINT and STAR are presented in this paper. These 
ICU patients have been treated by intensive sliding-scale insulin 
infusion. The effectiveness and safety of glycaemic control are 
then analysed.  Results showed that patient safety improved by 
83% with SPRINT and STAR protocol as the number of 
hypoglycaemic patients significantly reduced (BG<2.2 mmol/L).  
Percentage of time within desired bands and median BG 
improves in both SPRINT and STAR. However, the 
improvements are associated with higher number of BG 
measurements (workload). 
Keywords—model-based protocol; hyperglycaemia; ICU 
patients.  
I.  INTRODUCTION  
Stress-induced hyperglycemia is prevalent in the intensive 
care unit (ICU), occurring in patients even without prior 
diabetes [1]–[3]. Hyperglycaemia worsens outcomes, namely 
increasing the risk of severe infection, myocardial infarction, 
multiple organ failure and at worst, mortality [1]. Many 
studies [4], [5] demonstrated that tight glucose control (TGC) 
may lessen ICU patients’ mortality and other negative 
outcomes. A lot of TGC studies, either successful or 
unsuccessful had adopted nurse-implemented protocol that 
comes with some disadvantages: to name a few, as protocols 
are not individualized it is more of a one-size fits all method, 
some protocols may be ad-hoc or based on experience. 
Furthermore, providing round the clock care for ICU patients 
while adopting TGC has proven to be taxing.  
 
One approach to develop a glycaemic control protocol that 
can be implemented within ICU is through model-based 
method. Model-based protocols deliver patient specific 
control where the control protocol can be devised 
individually. Through model-based methods, virtual trials 
may be simulated to design or develop protocols in-silico. 
Herewith attention to control glycaemia either through feed 
and/or insulin (subcutaneous, IV, bolus) may be evaluated and 
devised. Glycaemic control protocol may be optimized 
virtually to save time, money and most importantly to yield a 
better patient outcome. 
SPRINT [4], a model-derived protocol was first 
implemented in Christchurch Hospital Department of 
Intensive Care in August 2005 and has treated over 1500 
patients. SPRINT protocol has been effective at decreasing 
organ failure and mortality [6], [7] giving the most secure 
control over all patients of several extensive studies [8], [9].  
It modulates both nutrition and insulin to provide tight 
glycaemic control. Insulin and dietary inputs are taken into 
account on hourly or 2-hourly blood glucose (BG) 
measurements for TGC. The protocol specifies carbohydrate 
intake, formula and/or goal feed rates [10], [11].  SPRINT is 
a paper-based protocol, developed through extensive 
computer simulations and does not require a bed-side 
computer.  
 Stochastic Targeted protocol (STAR) [12], downloadable 
on a tablet is a model-based protocol that uses a clinically 
validated glucose-insulin model which provides patient 
specific recommendations of insulin and nutrition while 
ensuring a 5% maximum risk of hypoglycaemia. STAR can 
be adopted over a scope of clinical scenarios and used for real-
time bedside care. The adaptability of STAR includes to local 
nutrition practices, desired BG target levels,  
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TABLE 1 SOCIO-DEMOGRAPHIC CHARACTERISTICS 
 
measurement frequency and patient safety within a predefined 
risk management approach [12], [13]. Since 2011, 2 ICUs 
have used STAR as the standard of care, namely Christchurch 
Hospital ICU, New Zealand and Kalman Pandy Hospital ICU, 
Guyla, Hungary. 
This study aims to assess, evaluate and compare the 
current clinical practice in a Malaysian ICU setting, Hospital 
Tengku Ampuan Afzan (HTAA) against SPRINT and STAR 
protocol performance using Malaysian critically-ill data. Both 
SPRINT and STAR protocols have managed to achieved BG 
band within 4.4-8.0 mmol/L at 93% and 86.6% respectively  
in clinical trials [12]. It would be interesting to see how 
Malaysian ICU patient that has been treated with intensive 
sliding-scale insulin infusion therapy fares against model-
based/model-derived protocol. Assessment and comparison of 
protocols are done through virtual trials, focusing on 
efficiency, safety and overall glycaemic control. Virtual trials 
provide the requirement to design the protocol in-silico by 
testing on virtual patient (actual patient data) to optimize 
protocol performance and safety without risk on actual 
patient. The simulation results would provide a basis of 
guideline if HTAA ICU would opt for a model-based/derived 
control protocol in future [14]. 
II. METHODS 
A. Patients Data 
Virtual trials were performed on retrospective data of 91 
critically ill patients treated under intensive sliding-scale 
insulin infusion at the ICU of HTAA. The socio-demographic 
characteristics and cohort details are summarized in Table 1. 
Malay ethnicity makes the largest cohort at 89% and 
percentage of male patients is 54%. 69% of patients are under 
medical category and 63% of patients fall under age cohort of 
over 50 years old. The intensive insulin protocol used in 
HTAA to maintain BG concentration target was set at 5.1-8.0 
mmol/L. The study was registered under the National Medical 
Research Register (NMR-13-1592-18706). Ethics was 
granted by IIUM Research Ethics Committee and National 
Institute of Health (NIH). 
B. HTAA Sliding Scale Protocol 
The flowchart in Figure 1 shows the intensive insulin 
infusion protocol adopted in the ICU of HTAA.  BG target is 
between 5.1 mmol/L – 8.0 mmol/L. Monitoring of BG is done 
hourly once insulin is administered and when there is no 
requirement of insulin rate change for 2 consecutive hours, 
BG is then measured 2 hourly. Frequency of monitoring is less 
once patient is considered stable. For detailed description of 
the protocol, refer to Figure 1. 
C. System Model 
The glucose-insulin physiological model utilized as a part 
of this study is clinically-validated [15]. Known as ICING 
[15] model, it utilizes past and current BG values, past 
nutrition past insulin measurements to register the insulin 
sensitivity, SI of the patient over the previous time period, 
based on parameter identification algorithm [16]  which fits 
the model to the clinically observed behavior.  
D. SPRINT Protocol 
SPRINT [6] protocol was implemented as a clinical 
practice change in intensive care unit of Christchurch 
Hospital in 2005. The entry criterion for the SPRINT protocol 
was a BG measurement of greater than 8 mmol/L on normal 
patient where 8 mmol/L represents higher glycaemic level. 
The BG measurement was taken hourly to ensure tight 
control and once patient is stable, two-hourly measurement is 
used. SPRINT will stop once patient is adequately self-
regulating and stable for 6 or more hours with over 80% of 
the target feed [10], [11]. SPRINT has a lower and tighter BG 
target at 4.4-6.1 mmol/L. 
 
E. STAR Protocol 
The STAR (Stochastic Targeted) [12],  glycaemic control 
protocol, has been used in Christchurch Hospital ICU since 
June 2011 [12]. Starting criteria for STAR is two continuous 
BG measurements over 8 mmol/L within a 4-hr period. The 
BG target range of STAR is 4.4 -8.0 mmol/L. This protocol 
utilizes a physiological glucose-insulin framework combined 
with stochastic models of SI inconstancy [17], [18] to decide 
the most fitting insulin and nutrition treatment combination. 
SI is an important indicator in clinical blood glucose (BG) 
control as it demonstrate the overall glycaemic reaction of a 
body to exogenous insulin and nutrition inputs.  
This measure of glycaemic reaction to exogenous sources 
of info is especially important for STAR which expects to 
minimize the danger of hypoglycaemia by straightforwardly 
representing likely fluctuation of SI. 
Socio - Demographic 
Characteristics 
Total N = 91
Gender
Female 42 
Male 49 
Mortality 
Unknown 
Dead 
Alive 
3 
35 
53 
Admission Category 
Surgical 28 
Medical 63 
Age groups (years) 
< 29 10 
30-39 10 
40-49 14 
> 50 57 
Ethnicity 
Indian 2 
Others 3 
Chinese 5 
Malays 81 
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Fig 1. HTAA Intensive Insulin Protocol 
F. Virtual  Trials 
Virtual trials have played an important part in tight 
glycemic control by providing safe and efficient way to 
analyze, develop or validate glycemic controls protocol. 
Figure 2 shows the steps of virtual trials starting from fitting, 
followed by simulation. The resulting time-varying SI 
profiles represent time-varying metabolic status for 
individual patients. This profile can be used to simulate the 
BG level for different insulin and dextrose inputs, associated 
with different control protocols. Thus, virtual trials present 
the closest view of possible behaviors seen typically in 
clinical setting.  
 
 
 
Fig.2: Virtual trial process 
 
G. Analysis 
The efficacy of SPRINT and STAR protocol on HTAA ICU 
patients is assessed in terms of performance and safety. A 
statistical Mann-Whitney U test was also done where a p-
value < 0.05 was considered to be significant.  
 
Metrics compared: 
 
• Performance: Percentage of time in BG band (4.0-6.1 
mmol/L, 4.4.-7.0 mmol/L, 4.4-8.0 mmol/L and 8.0-10 
mmol/L). Median and interquartile (IQR) of BG levels. 
 
• Safety    : Number of patients with moderate 
hypoglycaemia (BG< 4.4 mmol/L) 
 
• Safety    : Number of patients with severe 
hypoglycaemia (BG< 2.2 mmol/L) 
 
 
III. RESULTS  
 
Table 2 presents the virtual trial results of glycaemic control 
performance between HTAA (actual clinical data), SPRINT 
protocol and STAR protocol.  
 
        Figure 3 until Figure 5 illustrate the per-patient 
cumulative distribution functions (CDFs) of BG levels from 
actual clinical data of HTAA ICU and the performance of 
SPRINT protocol and STAR protocol, respectively. From 
Figure 3, Figure 4 and Figure 5 it can be seen that control of 
BG are tightest with STAR protocol. Outliers in Figure 3 can 
be seen, representing patients whom are not effectively 
controlled with BGs recorded at over 30 mmol/L. In SPRINT 
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protocol, these outliers are tighter and in Figure 5 under 
STAR protocol, the CDF of BG is smoother with 95th 
percentile of patients recorded BG lesser than 11 mmol/L. 
 
TABLE.2 VIRTUAL TRIALS OF STAR PROTOCOL AND SPRINT 
PROTOCOL IN COMPARISON TO CLINICAL DATA UNDER 
SLIDING-SCALE PROTOCOL AS PRACTICED IN HTAA ICU. 
 
IV. DISCUSSIONS 
          
Percentage of BG time band within 4.4-8.0 mmol/L is almost 
the same for SPRINT and STAR protocol at 52% and 51.95% 
as compared to HTAA at 45.16%. Generally, the overall 
performance is similar although higher percentage is 
obtained in SPRINT and STAR protocol. The trend is similar 
across other time band (4.0-6.1 mmol/L and 4.4 -7.0 mmol/L) 
where SPRINT protocol has the highest percentage. This 
result differs from what has been achieved by SPRINT and 
STAR in other clinical trials where over 86% of the time BG 
is within the desired time band (4.4-8.0 mmol/L) [12]. 
 
 
Fig 3 Cumulative distribution frequency (CDF) for Clinical 
data 
 
 
Fig 4 Cumulative distribution frequency for SPRINT 
Protocol 
  
sn
 
Fig 5 Cumulative distribution frequency for STAR Protocol 
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The explanation for this might lies under the cohort 
characteristics differences, particularly the SI. Figure 6 
illustrates the CDF of SI for Malaysian ICU against SPRINT 
ICU patients. It can be seen here that the SI of Malaysian 
patients are lower. SI is central model parameter of interest 
as response to insulin can change dramatically between 
patients. A closer look is needed to analyze the clinical 
conditions that might be associated with lower SI. In HTAA, 
69% of the patients are treated due to medical conditions 
which explain the lower SI.  
 
 
 
Fig 6 Cumulative distribution frequency versus Insulin 
sensitivity for HTAA and SPRINT Protocol 
 
In Figure 7, it is illustrated that the distribution of SI over the 
2 cohorts are significantly different. It is clear that SPRINT 
patients has a wider and flatter SI distribution. Patients in 
SPRINT has greater inter-patient variability whereas HTAA 
has less variability of SI. But even so, both SPRINT and 
STAR protocols with proven results in attaining higher BG 
median, higher percentage time in desired band, couldn’t 
obtain the same level of percentage through virtual trials.  
 
 
Fig 7 HTAA and SPRINT Protocol distributions of SI. 
 
 
       Better glycaemic outcomes in terms of patients safety is 
clearly achieved in STAR protocol where percentage of 
BG>10 mmol/L is reduced by 29.3%. SPRINT protocol on 
the other hand reduced 16.6% of BG> 10 mmol/L. Higher 
percentage in reduction of mild hypoglycaemia is 
demonstrated  by  SPRINT  protocol  (BG<4.4  mmol/L)  by 
56% and STAR by 42%. Both SPRINT and STAR only had 
1 patient with severe hypoglycaemia (BG<2.2 mmol/L), an 
83% improvement. This supports the capability of SPRINT 
and STAR that firmly controls glycaemia particularly 
patients who are in danger of hypoglycaemia. 
Control efficiency is associated with higher insulin 
inputs, and evident here as STAR protocol has the highest 
insulin rate at 6 U/hr, which is 4 Units higher than HTAA. 
Feeding is lower with 3.6 g/hr in STAR, 2 g/hr in SPRINT 
and 4.1 g/hr in HTAA. These results show that feed reduction 
is related to better glycaemic levels. Glycaemic control might 
be difficult to achieve with higher feeding rate but nutrition 
rules used in STAR still corresponds to 100% ACCP 
guidelines. 
 The key point seen here in these virtual trial results 
lies with the capacity of SPRINT and STAR in providing safe 
glycemic control is often challenging within ICU patients. 
This is something that is unique to model-based protocol as 
has been demonstrated and achieved by STAR protocol.  
 However there are many other area and issues that 
will be worthy to look at. For example, clinical integration 
that requires compliance of staff, differences in patient cohort 
(surgical, medical, cardio), diabetic status, differences in feed 
target practice etc. All these points when put into 
consideration might bring us to a different explanation to the 
virtual trials presented in this paper.  
V. CONCLUSIONS 
 
 
This study presented an analysis of clinical practice from an 
ICU in HTAA, simulated with SPRINT and STAR protocols. 
Through virtual simulations, patient’s safety has been 
improved by 83% where only 1 patient had a severe case of 
hypoglycaemia. Overall, both SPRINT and STAR protocols 
have shown the ability in providing a safe and effective 
treatment. Thus, a model-based approach can safely be 
adopted and introduced into a Malaysian ICU settings 
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